Continuous antibiotic prophylaxis prevents recurrent UTIs in patients who self-catheterise

Continuous low-dose antibiotic prophylaxis is effective in reducing the frequency of recurrent UTI in patients who practise clean intermittent self-catherisation (CISC), according to a new study.

Repeated symptomatic UTIs affect 25% of people who practise clean intermittent self-catheterisation. | DR P. MARAZZI/SCIENCE PHOTO LIBRARY
Repeated symptomatic UTIs affect 25% of people who practise clean intermittent self-catheterisation. | DR P. MARAZZI/SCIENCE PHOTO LIBRARY

Adults who practise CISC and experience repeated UTIs are likely to benefit from antibiotic prophylaxis, a study published in The Lancet Infectious Diseases has shown, although this approach could increase antimicrobial resistance.

In a randomised, open-label, superiority trial, Holly Fisher and colleagues enrolled 404 community-dwelling users of CISC who had recurrent UTIs. The researchers randomly allocated participants to receive either antibiotic prophylaxis once daily (prophylaxis group, n=203) or no prophylaxis (control group, n=201) for 12 months.

The primary analysis included 181 adults allocated to the prophylaxis group and 180 adults in the control group; the remaining 43 participants were missing follow-up data before 6 months.

The analysis showed that the incidence of symptomatic antibiotic-treated UTIs over 12 months (primary endpoint) was halved by the use of antibiotics, with 1.3 cases per person-year (95% CI 1.1–1.6) in the prophylaxis group and 2.6 cases per person-year (95% CI 2.3–2.9) in the control group. The incidence rate ratio was 0.52 (0.44–0.61; p<0.0001), indicating a 48% reduction in UTI frequency with antibiotic prophylaxis.

Antibiotic resistance

Antibiotic prophylaxis was well tolerated: there were 22 minor adverse events in the prophylaxis group related to antibiotic prophylaxis during the study, predominantly gastrointestinal disturbance (6 participants), skin rash (6 participants), and candidal infection (4 participants). However, resistance against the antibiotics used for UTI treatment was more frequent in urinary isolates from the prophylaxis group than in those from the control group at 9–12 months of trial participation (nitrofurantoin 24% vs 9%, p=0.038; trimethoprim 67% vs 33%, p=0.0003; and co-trimoxazole 53% vs 24%, p=0.002).

Importantly, the authors assessed episodes of symptomatic UTIs rather than merely bacteriuria (which is not a clinically meaningful endpoint). However, caution is required in interpreting the results as the study was not placebo-controlled and the primary outcome was determined on the basis of patient-reported outcomes.

'The long-term implications of this intervention are uncertain, but increased pathogen resistance might make it more difficult to treat established infections in individuals, and increased resistance of bacteria that colonise urine and contribute to the faecal microbiome are a public health concern,' said the authors.

'The severity of individual patient distress from repeated UTIs and local threats from antimicrobial resistance should simultaneously be considered when appraising and implementing this evidence of benefit of treatment.'

Repeated symptomatic urinary tract infections (UTIs) affect 25% of people who use clean intermittent self-catheterisation (CISC) to empty their bladder.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

A head shot of a smiling Dr Richard Russell.

Free webinar: are COPD and CVD ‘two sides of the same coin’?

MIMS Learning is hosting a free webinar on 13 June...

Xray image of a hip fracture

NICE approves osteoporosis drug for postmenopausal women

Romosozumab (Evenity) has been recommended by NICE...

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

A young man lies awake in bed with his bedside clock showing the time as 2.11am.

Insomnia app recommended by NICE

GPs can now offer an app-based treatment programme...